Afrocentric Investment (JSE:ACT) COGS-to-Revenue : 0.42 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Afrocentric Investment COGS-to-Revenue?

Afrocentric Investment's Cost of Goods Sold for the six months ended in Dec. 2023 was R1,838 Mil. Its Revenue for the six months ended in Dec. 2023 was R4,384 Mil.

Afrocentric Investment's COGS to Revenue for the six months ended in Dec. 2023 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Afrocentric Investment's Gross Margin % for the six months ended in Dec. 2023 was 58.07%.

Afrocentric Investment COGS-to-Revenue Historical Data

The historical data trend for Afrocentric Investment's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Afrocentric Investment COGS-to-Revenue Chart

Afrocentric Investment Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.23

0.24

0.46

0.45

Afrocentric Investment Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.23	0.68	0.45	0.45	0.42

Afrocentric Investment COGS-to-Revenue Calculation

Afrocentric Investment's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3976.432	/	8868.032
	=	0.45

Afrocentric Investment's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1838.355	/	4384.386
	=	0.42

Afrocentric Investment (JSE:ACT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Afrocentric Investment's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1838.355 / 4384.386
	=	58.07 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Afrocentric Investment COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Afrocentric Investment's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Afrocentric Investment (JSE:ACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Afrocentric Investment Corp Ltd (JSE:ACT) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

37 Conrad Road, Florida North, Roodepoort, ZAF, 1709

Website

http://www.afrocentric.za.com

Afrocentric Investment Corp Ltd is a black-owned investment holding company with an investment portfolio focused on services to the healthcare sector. It seeks to invest in healthcare-related businesses that demonstrate prospects for growth as well as diversify its revenue sources while contributing to the sustainable health and welfare of South African communities. The company provides health administration and health risk management solutions to the healthcare industry. It also provides a range of complementary services to its traditional medical scheme clients and a portfolio of healthcare-related enterprises. These services include information technology solutions, transactional switching, specialized disease management, pharmaceutical wholesaling, amongst others.